CHICAGO, July 01, 2021 (GLOBE NEWSWIRE) — Cosmos Holdings, Inc. (“the Firm”) (OTCQX: COSM), a world pharmaceutical firm with a proprietary line of branded and generic prescription drugs, nutraceuticals, OTC drugs and an in depth, established European Union distribution community, right this moment introduced that it has appointed finance veteran Alexi Papaconstantinou to the Firm’s Advisory Board.
Mr. Papaconstantinou is a capital markets veteran and brings over 20 years of expertise in funding banking, fairness financing, portfolio administration and mergers and acquisitions with a specific concentrate on high-growth private and non-private firms. Mr. Papaconstantinou is presently the Co-founder and Managing Accomplice of Lacerta Companions, a household workplace backed multi-strategy fund. Previous to Co-founding Lacerta Companions, Mr. Papaconstantinou served as Portfolio Supervisor/Senior Funding Analyst at plenty of well-known hedge funds, together with Level72 and Moore Capital Administration in London. Earlier in his profession, Mr. Papaconstantinou held varied positions throughout the Funding Banking Division at Morgan Stanley in London, the place he labored on quite a few M&A and capital markets transactions throughout a broad spectrum of industries together with transport, monetary establishments, retail, and pharma. Mr. Papaconstantinou obtained a B.A. in Economics and graduated Magna cum laude from Yale College.
Greg Siokas, Chief Government Officer of Cosmos Holdings, said, “We’re happy to welcome Alexi to our advisory board. Alexi brings with him a formidable monitor report in company finance and capital markets in addition to mergers and acquisitions, which must be invaluable as we proceed to aggressively broaden our world footprint, each organically and thru acquisitions. Moreover, we imagine having an skilled finance veteran of Alexi’s caliber will help us in reaching an inventory on a senior nationwide alternate and assist us to take care of the very best ranges of company governance.”
Mr. Papaconstantinou commented, “I’m delighted to be becoming a member of such a progressive, growth-oriented firm as Cosmos. I stay up for working with administration to reinforce shareholder worth as Cosmos continues to broaden its sturdy distribution community and launch new and progressive pharmaceutical and nutraceutical merchandise in several markets worldwide.”
About Cosmos Holdings, Inc.
Cosmos Holdings Inc. is a world pharmaceutical firm, with a proprietary line of branded and generic prescription drugs, nutraceuticals, OTC drugs and medical gadgets and an in depth, established EU distribution community. The Firm identifies, acquires, develops and commercializes merchandise that enhance sufferers’ lives and outcomes and has developed a worldwide distribution platform with shoppers in 16 European international locations and presently increasing all through Asia and North America. Cosmos Holdings has workplaces and distribution facilities in Thessaloniki, Greece, Athens, Greece and Harlow, UK. Extra data is out there at www.cosmosholdingsinc.com and www.skypremiumlife.com.
Except the historic data contained on this information launch, the issues described herein, might comprise forward-looking statements throughout the that means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Alternate Act of 1934, as amended. Statements preceded by, adopted by, or that in any other case, embody the phrases “believes,” “expects,” “anticipates,” “intends,” “initiatives,” “estimates,” “plans” and related expressions or future or conditional verbs similar to “will,” “ought to,” “would,” “might” and “might”, are typically forward-looking in nature and never historic info, though not all forward-looking statements embody the foregoing. These statements, contain unknown dangers and uncertainties which will individually or materially affect the issues mentioned, herein for a wide range of causes which are exterior the management of the Firm, together with, however not restricted to, the Firm’s potential to lift adequate financing to implement its marketing strategy, the affect of the COVID-19 pandemic on the Firm’s enterprise, operations and the financial system usually, and the Firm’s potential to efficiently develop and commercialize its proprietary merchandise and applied sciences. Readers are cautioned to not place undue reliance on these forward- wanting statements, as precise outcomes might differ materially from these described within the forward-looking statements contained herein. Readers are urged to learn the danger elements set forth within the Firm’s filings with the SEC, which can be found on the SEC’s web site (www.sec.gov). The Firm disclaims any intention or obligation to replace, or revise any forward-looking statements, whether or not on account of new data, future occasions or in any other case.
Investor Relations Contact:
Crescendo Communications, LLC
Electronic mail: COSM@crescendo-ir.com